{"symbol":"REGN","fiscalQuarter":"Q2-2009","reportDate":"2009-08-04","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2009","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 2.15%","keyNumbers":[{"metric":"EPS","actual":"$-0.19","expected":"N/A","surprise":"+32.86%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing research and development efforts.","They expressed confidence in future product pipeline potential."],"summary":"Overall, management conveyed a cautiously optimistic outlook regarding their ongoing projects. They emphasized the importance of their research initiatives."},"guidanceChanges":{"summary":"No guidance data is available for this quarter.","changes":[]},"whatItMeans":"Regeneron's earnings report showed a smaller-than-expected loss per share, which pleased investors and led to a 2.15% increase in the stock price. The positive EPS surprise indicates that the company is managing costs effectively despite not providing revenue figures. The management's focus on research and development suggests potential growth opportunities in the future.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2009 earnings: EPS beat expectations. Stock up 2.15%. Full breakdown."}}